The Federal Trade Commission (FTC) has launched an inquiry into allegations of deceptive practices within the realm of gender-affirming care, following testimony from detransitioners who claim to have been misled by the medical establishment. The agency is seeking input from individuals who believe they have been adversely affected by such treatments.
One detransitioner recounts their personal struggle, detailing the physical and emotional consequences of treatments that included puberty blockers and cross-sex hormones. They argue that the medical establishment misrepresented the effects of these interventions, leading to long-term health issues and a lack of informed consent. The individual also criticizes the system for prioritizing financial gain over patient welfare, highlighting the potential for exploitation within the gender care industry.
As the investigation progresses, the FTC aims to determine whether the medical industry has engaged in practices that could be deemed unfair or deceptive. The individual’s account, along with others, is intended to inform the regulatory body’s understanding of the potential risks and ethical concerns associated with gender-affirming care. The broader implications of this investigation could influence future policies and practices within the healthcare sector.